Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immunogenicity and Safety Study of VLA15, A Multivalent Recombinant OspA (Outer Surface Protein A) Based Vaccine Candidate Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. A Randomized, Controlled, Observer-blind Phase 2 Study

Next Previous
X
Search
Trial Profile

Immunogenicity and Safety Study of VLA15, A Multivalent Recombinant OspA (Outer Surface Protein A) Based Vaccine Candidate Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. A Randomized, Controlled, Observer-blind Phase 2 Study

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VLA 15 (Primary) ; Alum
  • Indications Lyme disease
  • Focus Pharmacodynamics
  • Sponsors Pfizer; Valneva

    • Most Recent Events

    • 01 Sep 2024 Results from two studies (NCT03769194 and NCT03970733) assessing VLA15 dose and schedule that induces highest and most durable antibody titres, without compromising safety published in The Lancet Infectious Diseases
    • 03 Jun 2024 According to a Valneva media release, companies aim to publish The Lancet results in a peer-reviewed medical journal.
    • 03 Jun 2024 According to a Valneva media release, today announced that the results of two Phase 2 clinical trials (VLA15-201 and VLA15-202) of Lyme disease vaccine candidate, VLA15, were published in the peer-reviewed medical journal, The Lancet Infectious Diseases

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top